Manual for Submission of Drug Clinical Development Dossier (DCDD) and Clinical Trial Specific Dossier v.1

Size: px
Start display at page:

Download "Manual for Submission of Drug Clinical Development Dossier (DCDD) and Clinical Trial Specific Dossier v.1"

Transcription

1 Manual for Submission of Drug Clinical Development Dossier (DCDD) and Clinical Trial Specific Dossier v.1 Brasília, 2015

2 Copyright Brazilian Health Surveillance Agency. Partial or complete reproduction of this document is permitted, as long as the source is referenced. Legal deposit at the National Library, in accordance with Decree n 1.825, of December 20th, Acting Director-President Jaime Cesar de Moura Oliveira Associate of Director-President Diogo Penha Soares Directors Ivo Bucaresky José Carlos Magalhães da Silva Moutinho Renato Alencar Porto Head of Office Luciana Shimizu Takara Superintendent of Drugs and Biological Products Meiruze Sousa Freitas Clinical Research Coordination for Drugs and Biological Products Patrícia Ferrari Andreotti Team Responsible for the Manual: Adriane Alves de Oliveira Flávia Regina Souza Sobral Kellen do Rocio Malaman Patrícia Ferrari Andreotti Ricardo Eccard da Silva Cooperation: André Luís Carvalho Santos Souza Bruno de Paula Coutinho Bruno Zago Franca Diniz Candida Luci Pessoa e Silva Carla Abrahao Brichesi Carlos Augusto Martins Netto Claudio Nishizawa Fanny Nascimento Moura Fernando Casseb Flosi Janaina Lopes Domingos Miriam Motizuki Onishi Sônia Costa e Silva

3 Manual for Submission of Drug Clinical Development Dossier (DCDD) and Clinical Trials Specific Dossiers 3 Table of Contents 1. Introduction DCDD Submission and Specific Clinical Trial Dossiers DCDD Submission Submission of Specific Clinical Trial Dossiers DCDD documents Drug Development Plan Investigator s Brochure Experimental Drug Dossier Issuance of Special Bulletin (SB) and Document for Importation of Investigational Product(s) Related to the Drug Clinical Development Dossier (DCDD) Secondary Petitions Transitional Provisions References... 19

4 Manual for Submission of Drug Clinical Development Dossier (DCDD) and Clinical Trials Specific Dossiers 4 1. Introduction Without prejudice to existing regulations in legal provisions, this manual is intended to additionally guide and explain submissions of Drug Clinical Development Dossiers (DCDD) and Specific Clinical Trial Dossiers.

5 Manual for Submission of Drug Clinical Development Dossier (DCDD) and Clinical Trials Specific Dossiers 5 2. DCDD Submission and Specific Clinical Trial Dossiers 2.1 DCDD Submission In accordance with Resolution which outlines Health Regulation regarding the conduct of clinical trials with drugs in Brazil, the Drug Clinical Development Dossier (DCDD) is the compilation of documents to be submitted to ANVISA with purposes of evaluating the stages related to the development of an experimental drug, in order to obtain information to support the registration or post-registration changes regarding the referred product. For the electronic application of a DCDD at ANVISA, the regulated department must inform one of the following primary petition subjects: CLINICAL TRIALS - Approval in Process of Drug Clinical Development Dossier (DCDD) Synthetic Drugs CLINICAL TRIALS - Approval in Process of Drug Clinical Development Dossier (DCDD) - Biological Products CLINICAL TRIALS - Approval in Process of Drug Clinical Development Dossier (DCDD) - Herbal Products CLINICAL TRIALS - Approval in Process of Drug Clinical Development Dossier (DCDD) - Radiopharmaceuticals CLINICAL TRIALS CRO Approval in Process of Drug Clinical Development Dossier (DCDD) Synthetic Drugs CLINICAL TRIALS CRO Approval in Process of Drug Clinical Development Dossier (DCDD) - Biological Products CLINICAL TRIALS CRO Approval in Process of Drug Clinical Development Dossier (DCDD) - Herbal Products CLINICAL TRIALS CRO Approval in Process of Drug Clinical Development Dossier (DCDD) - Radiopharmaceuticals The specific checklist for the abovementioned subjects can be searched at ANVISA website and they strictly follow the description of the items contained in the regulation. The applicant must submit a DCDD to ANVISA only if intended to conduct clinical trials with drugs in the country. DCDD applies only to the development of an experimental drug. For analysis purposes, DCDD must be submitted with at least one specific clinical trial dossier to be performed in Brazil, and it may be a clinical trial previously approved by ANVISA. Upon electronic petition of one of DCDD subjects, the applicant must answer the following question: Are there application processes filed with ANVISA to be linked to this DCDD?. If positive, the person responsible for petitioning must inform the process numbers of subjects for approval related to DCDD experimental drug, which were already submitted to ANVISA and that are part of the product clinical Development Plan. They may have already been analyzed, approved, rejected, canceled, or being

6 Manual for Submission of Drug Clinical Development Dossier (DCDD) and Clinical Trials Specific Dossiers 6 awaiting resolution of pending issues or expecting technical analysis. Therefore, approval processes already submitted to ANVISA must be linked to a single DCDD for each experimental drug. The following subjects previously petitioned at ANVISA may be linked to a DCDD: CLINICAL TRIALS CRO Approval in Clinical Research Process - Herbal Products CLINICAL TRIALS CRO Approval in Clinical Research Process - Synthetic Drugs CLINICAL TRIALS CRO Approval in Clinical Research Process - Biological Products CLINICAL TRIALS - Approval in Clinical Research Process - Herbal Products CLINICAL TRIALS - Approval in Clinical Research Process - Synthetic Drugs CLINICAL TRIALS - Approval in Clinical Research Process- Biological Products CLINICAL TRIALS - Approval in Clinical Research Process Drug Products CLINICAL TRIALS CRO Approval in Clinical Research Process -

7 Manual for Submission of Drug Clinical Development Dossier (DCDD) and Clinical Trials Specific Dossiers 7 Drug Products CLINICAL TRIALS - Notification in Clinical Research - Phase IV/Observational linkable to the DCDD The documents of a DCDD must be manually filed with ANVISA, in accordance with a specific checklist for the concerned subject, except for Specific Dossier(s) for each Clinical Trial which will be a new process, electronically petitioned and filed. 2.2 Submission of Specific Clinical Trial Dossiers The Specific Dossiers for each clinical trial must be submitted as primary petitions and, therefore, will have a process number, with specific subjects for each clinical trial to be conducted in Brazil and that have not yet been submitted to ANVISA. The Clinical Trial Specific Dossiers may be submitted to ANVISA as one of the following subjects: CLINICAL TRIALS - Approval in Clinical Research Process - Synthetic Drugs CLINICAL TRIALS - Approval in Clinical Research Process- Biological Products CLINICAL TRIALS - Approval in Clinical Research Process - Herbal Products CLINICAL TRIALS - Approval in Clinical Research Process - Radiopharmaceuticals CLINICAL TRIALS CRO Approval in Clinical Research Process - Synthetic Drugs CLINICAL TRIALS CRO Approval in Clinical Research Process - Biological Products CLINICAL TRIALS CRO Approval in Clinical Research Process - Herbal Products CLINICAL TRIALS CRO Approval in Clinical Research Process - Radiopharmaceuticals

8 Manual for Submission of Drug Clinical Development Dossier (DCDD) and Clinical Trials Specific Dossiers 8 DCDD 550- CLINICAL TRIALS - Notification in Clinical Research - Phase IV/Observational linkable to The specific dossiers for each clinical trial can be petitioned by institutions with CNPJ (tax ID number) different from the one informed in the DCDD. For submission of the above subjects, the following must be informed: DCDD process number to which the petition for Application in Clinical Research Process shall be linked to, because the system does not allow petitioning of these subjects without relating to a DCDD. Specific Dossiers for each Clinical Trial can be petitioned by institutions with Corporate Taxpayers Registry (CNPJ) different from the one informed in DCDD. For petition of the above subjects, the following must be informed: DCDD process number to which the petition for Approval in Clinical Research Process shall be linked to, because the system does not allow petitioning of these subjects without being related to a DCDD. The specific checklist for each of the abovementioned subjects may be referenced at ANVISA website and those strictly follow the description of items required by current regulation. Petitioning and filing must be electronically performed. For each item contained in the checklist of such petitions, the applicant will need to attach at least one PDF file, with textual search allowed. It will be possible to attach up to five 750-Kb files. For greater clarity, we recommend that the appendix concerning the protocol is identified as Protocol. For the continuity of the petitioning process, each attached file needs to be viewed. After the petitioning completion, a transaction number is generated. In cases of taxes collection, no changes can be made to the submitted dossier after payment of the referred tax. Any subsequent changes can be performed through the subject-specific codes. It is emphasized that petitions should only be submitted for dossiers of clinical trials to be conducted in Brazil. Only dossiers which have already clinical and non-clinical support to be started should be filed, because the Special Bulletin (SB) issued to DCDD will contain only clinical trials that ANVISA considers that can be started. If a Development Plan is comprehensively presented, containing Phases 1, 2, and 3 clinical trials, but with early stage studies ongoing, which are not able to support late stage clinical trials, the phase 3 trial, for example, should not be initially petitioned at ANVISA. This clinical trial may be petitioned after there are already sufficient clinical and non-clinical data to support its initiation. It may later be included as a petition of subjects of the Clinical Trial Specific Dossiers, if it is not different from what was already presented in the Development Plan; or it may be petitioned as a Substantial DCDD Change ( CLINICAL TRIALS - DCDD Change - Inclusion of clinical trial protocol not foreseen in the initial development plan) for cases where there is a change in the Development Plan.

9 Manual for Submission of Drug Clinical Development Dossier (DCDD) and Clinical Trials Specific Dossiers 9 The foregoing provisions do not apply to the Drug Development Plan (described in detail in Section 6), where all trials planned for that experimental drug should be described, regardless those are to be conducted in Brazil or not.

10 Manual for Submission of Drug Clinical Development Dossier (DCDD) and Clinical Trials Specific Dossiers DCDD documents For the DCDD submission, Section II, Chapter III of the new Health Regulations for Clinical Trials with Drugs should be followed. We recommend that all documentation be submitted in Portuguese, especially the clinical protocol and the investigator's brochure, since it is established in RDC 50/2013 that the evaluator of the technical area might issue pending requiring translation of the presented documentation. Below is a description of some documents to facilitate the submission of the DCDD. 3.1 Drug Development Plan The preparation of a Development Plan by the study sponsor enables the establishment of goals and methodologies, making possible the identification of critical steps and challenges of the process as well as planning the monitoring actions, based on established indicators. Information available on the experimental drug shall support the proposed clinical indication, the target population and the types of proposed clinical trials designs. The Drug Development Plan should explain the required steps for clinical research of the experimental drug. In short, the plan must show all rationale for drug development, forecasting all the steps which have already been performed, that are in progress and are intended for the clinical research of the drug. The Development Plan shall also indicate clinical trials that have been, are being or will be held outside Brazil. The agency recommends that a table or a schematic drawing is included, containing all clinical trials planned for clinical development during a certain period of time as well as the progress of these trials (completed, in progress or planned).

11 Manual for Submission of Drug Clinical Development Dossier (DCDD) and Clinical Trials Specific Dossiers 11 The Development Plan should be initiated with a brief description of the experimental drug, informing the AFI (Active Pharmaceutical Ingredient), category of the drug, therapeutic class (according to the ATCC - Anatomical Therapeutic Chemical Code) and route of administration. The indication(s) must be technically justified through the experimental drug mechanism of action, demonstrating that it is directly or indirectly involved in the diagnostic or therapeutic effect. This topic should only include the indication(s) proposed in the Development Plan. The sponsor should also inform the general objectives listing all indications intended for the experimental drug, even those which are not yet being investigated in the presented Development Plan. In addition, the planned duration of the proposed clinical development must be informed. Additionally, the sponsor should provide a brief description for all clinical trials included in the Development Plan, providing information on the phase, design, outcomes, comparators, objectives, the population to be studied, the hypothesis(es) to be tested, estimated number of participants and statistical plan. ANVISA recognizes that the Development Plan is not static and that it can be changed throughout an experimental drug s development. In the Development Plan, results of clinical trials that have already been done do not need to be presented. The results of clinical trials should be presented in the Investigator's Brochure. If the experimental drug is already recorded in Brazil, only information pertaining to proposed postregistration amendments must be submitted in the Development Plan.

12 Manual for Submission of Drug Clinical Development Dossier (DCDD) and Clinical Trials Specific Dossiers Investigator s Brochure The Investigator's Brochure (IB) is a document containing the compilation of the non-clinical and clinical data of an experimental drug that are relevant to its study in humans. Its goal is to provide researchers and others involved in the conduct of the clinical trial with information on the dose, dosing regimen, methods of administration and safety monitoring procedures. The IB also provides support for the monitoring of clinical trial participants during its conduction. In the meantime, information should be presented in a concise, clear, simple and objective language to better guide researchers while conducting the clinical trial. This item in the manual aims to clarify the minimum information that should be included in an IB. According to the development phase of the experimental drug and its category, the degree of detail of information available may vary. If a drug already marketed is being investigated for a new indication or a new population, the IB must contain information justifying and supporting this new condition. The IB must contain a brief description of the experimental drug, its chemical characterization, biological activity, and formulation, the characterization of pharmacological and toxicological effects of the experimental drug in animals and humans, when applicable, safety and efficacy information in humans obtained from clinical trials already carried out, as well as any critical information about the experimental drug. The IB must present data that are already known, available results of non-clinical and clinical studies, as well as ongoing studies and their preliminary data, if any. The IB must specify the description of possible risks and adverse events related to the experimental drug based on past experience, as well as precautions, safety warnings or special monitoring requirements, including from other regulatory authorities, to be followed during development, to better guide researchers who will lead the study. 3.3 Experimental Drug Dossier Documents relating to items a, b, c, d, and f of the experimental drug dossier described in the regulation will be addressed in a specific guide of technical evaluation of investigational products. Thus, this item will only address subparagraphs g and h of

13 Manual for Submission of Drug Clinical Development Dossier (DCDD) and Clinical Trials Specific Dossiers 13 Section II, Chapter III - Application Content and Format - of the new regulation. The critical analysis of non-clinical studies must provide for the following aspects: i. Support for the choice of the types of tests and animal models chosen, and discuss possible methodological limitations of tests already carried out. Tests should support the clinical indication being studied, route of administration and equivalent dose in humans. ii. Discuss the findings in animal models with identification of target organs and possible implications of these findings in humans. Demonstrate that the safety profile of the experimental drug, based on the results of pharmacological and toxicological studies, is acceptable for clinical research. iii. Evaluate the possible benefits and risks involved to support the conduct of the experimental drug s clinical development. iv. Present information on sites where the studies were conducted, as well as where their records are available for inspection, including a statement that each study was conducted in accordance with Good Laboratory Practice or a justification for the absence of such statement. The critical analysis of clinical studies already performed must provide for the following aspects: i. Discuss the scientific quality of clinical trial data based on the level of evidence and grade of recommendation of available evidence. Also, discuss the possible methodological limitations of clinical trials already conducted and the procedures used for controlling systematic errors. ii. Based on non-clinical testing data, present a discussion on the safety monitoring in clinical development. iii. Support the choice of safety and efficacy outcomes used in previous studies. These outcomes should be aligned with the objectives and hypotheses. iv. In case of post-registration changes, such as expansion of use, new therapeutic indication, new pharmaceutical form, among others, explain the choice of the type of design, study population, dose regimens and other relevant aspects related to the changes. v. Risk management should be guided by results of previous studies as death or other serious adverse events, type of sequelae due to these events, assessments and recommendations of the Independent Safety Monitoring Committee,

14 Manual for Submission of Drug Clinical Development Dossier (DCDD) and Clinical Trials Specific Dossiers 14 tolerability, toxicological findings, pharmacological safety (cardiovascular, respiratory, and nervous systems), among others. In addition, recommendations from other agencies for the proposed study or the experimental drug should be taken into consideration. vi. Present the assessment of the balance between possible benefits and risks involved to support the continued clinical development of the experimental drug.

15 Manual for Submission of Drug Clinical Development Dossier (DCDD) and Clinical Trials Specific Dossiers Issuance of Special Bulletin (SB) and Document for Importation of Investigational Product(s) Related to the Drug Clinical Development Dossier (DCDD) According to the resolution, Special Bulletin (SB) is the authorizing document issued by ANVISA, after DCDD analysis and approval, and can be used in import or export requests for a clinical trial. All clinical trials authorized to be conducted in Brazil are described in the SB. Therefore, only clinical trials listed in the SB can be initiated in Brazil, respecting all other ethical approvals. The SB also contains the list of products to be imported for each clinical trial, as well as storage conditions and shelf life. This information is provided by the applicant when completing the Form for clinical trial presentation. If new clinical trials are included or excluded, if products to import are included or excluded, or if storage conditions and shelf life are changed, an updated SB shall be issued. Information relating to the inclusion of Clinical Trials not foreseen in the Development Plan must be provided to ANVISA through the subjects: CLINICAL TRIALS - DCDD Modification - Clinical trial protocol inclusion not foreseen in the initial development plan. In cases of inclusion of protocol(s) already foreseen in the initial development plan, only the submission through the subject(s) listed in Section 2.2 of this Manual will be required. As for exclusion of protocols, the information will be provided through the subject: CLINICAL TRIALS - DCDD Modification - Clinical Trial Protocol Exclusion. For changes in the information about the products under investigation, such as storage conditions and shelf life, the following subject should be petitioned CLINICAL TRIALS Modification to Form for clinical trial presentation. For cases when there is no manifestation from ANVISA, according to the new Health Resolution for Clinical Trials with drugs, a document for importation of

16 Manual for Submission of Drug Clinical Development Dossier (DCDD) and Clinical Trials Specific Dossiers 16 product(s) under investigation by the Drug Clinical Development Dossier (DCDD) is sent, to allow import of products needed to conduct the Clinical Trials. This document contains the same information of the SB regarding Clinical Trials and products to be imported. Therefore, in cases of changes to this information, the same criteria and subjects presented for amendments to the SB must be followed. After sending the relevant documentation to allow changes by the applicant, an updated document for importation of product(s) under investigation by the Drug Clinical Development Dossier (DCDD) will be issued.

17 Manual for Submission of Drug Clinical Development Dossier (DCDD) and Clinical Trials Specific Dossiers Secondary Petitions Secondary petitions must be linked to their respective specific processes, i.e. secondary petitions related to a DCDD shall be filed to the application process of the Drug Clinical Development Dossier (DCDD). Some examples of DCDD petitions are: Subjects of DCDD Modification, Change to the DCDD Petition Form, Safety Update Report for development of the experimental drug, DCDD Cancellation Request, DCDD Cancellation due to Global Transfer of Responsibility by the Sponsor in charge, Temporary Suspension of DCDD, Reactivation of Suspended DCDD. Similarly, petitions related to Clinical Trial Dossiers should be linked to their respective clinical trial processes. Examples of Clinical Trial Dossiers petitions are: Change to Form for clinical trial presentation, Substantial Amendment to Clinical Protocol, Annual Report for Clinical Trial Protocol Monitoring, Clinical Trial Protocol Cancellation Request, Clinical Trial Protocol Cancellation due to Global Transfer of Responsibility, Temporary Suspension of Clinical Trial Protocol, Reactivation of Suspended Clinical Trial Protocol. The linking of secondary petitions to their corresponding processes is critical to their analysis and traceability within ANVISA s electronic systems. Secondary petitions shall be filed electronically. For each item contained in the check-list of these petitions, the applicant will need to attach at least one PDF file, with textual search enabled. It is possible to attach up to five 750-Kb files. For the continuity of the petitioning process, each attached file will need to be viewed. After completion of the petitioning process, a transaction number will be generated. In cases of taxes collection, no changes can be made to the submitted dossier after payment of the referred tax. Any subsequent changes can be performed through the subject-specific codes. 6. Transitional Provisions The application processes in clinical trials filed within ANVISA which predate the publication of the new resolution and that are still awaiting technical analysis will be evaluated according to the resolutions in effect at the time of their submission.

18 Manual for Submission of Drug Clinical Development Dossier (DCDD) and Clinical Trials Specific Dossiers 18 In cases of petitions that are within the 90 (ninety) days scope described in the Transitional Provisions of the Health Regulations for the conduct of clinical trials with drugs in Brazil, a SSB will be issued for import purposes, according to the resolution in effect at the time of their submission. This SSB will be needed to import requests as established in RDC 39/2008, that is, for these cases a pre-shipment approval from the technical area (COPEC) and a post-shipment approval (location of unloading) will be needed. For processes falling outside the scope of 90 (ninety) days, it will be necessary to hold for approval of the clinical trial by ANVISA, as provided in the Resolution current at the time of filing and the import process will also occur as foreseen in RDC 39/2008. The applicability for the processes assessment in accordance with current resolutions at the time of filing also includes the analysis of other secondary petitions linked to them, such as: sites inclusion or exclusion, change of principal investigator, change in the amount of products to be imported, among others.

19 Manual for Submission of Drug Clinical Development Dossier (DCDD) and Clinical Trials Specific Dossiers References Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance

Manual for Submission of Quality Data regarding the Investigational Products Used in Clinical Trials Biological Products

Manual for Submission of Quality Data regarding the Investigational Products Used in Clinical Trials Biological Products Manual for Submission of Quality Data regarding the Investigational Products Used in Clinical Trials Biological Products General Drug Management GCMED Coordination of Clinical Research on Drugs and Biological

More information

Brazilian Health Surveillance Agency ANVISA. General Management of Technology of Health Products GGTPS TECHNICAL NOTE NO. 004/2016/GGTPS/DIREG/ANVISA

Brazilian Health Surveillance Agency ANVISA. General Management of Technology of Health Products GGTPS TECHNICAL NOTE NO. 004/2016/GGTPS/DIREG/ANVISA Brazilian Health Surveillance Agency ANVISA General Management of Technology of Health Products GGTPS TECHNICAL NOTE NO. 004/2016/GGTPS/DIREG/ANVISA Object: Requirements to determine the need for clinical

More information

National Health Surveillance Agency. Public Consultation No. 255, dated June 19, 2017 D.O.U of 06/20/2017

National Health Surveillance Agency.  Public Consultation No. 255, dated June 19, 2017 D.O.U of 06/20/2017 National Health Surveillance Agency www.anvisa.gov.br Public Consultation No. 255, dated June 19, 2017 D.O.U of 06/20/2017 The Board of the National Health Surveillance Agency, in the use of the powers

More information

This template is to be used by companies willing to submit an overview of relevant

This template is to be used by companies willing to submit an overview of relevant Briefing book template for pharmaceuticals to support a multi-hta Early Dialogue (ED) December 13 th, 2013 This template is to be used by companies willing to submit an overview of relevant information

More information

A SHORT GUIDE TO THE PROCEDURE FOR A CLINICAL TRIAL APPLICATION IN THE KINGDOM OF BAHRAIN

A SHORT GUIDE TO THE PROCEDURE FOR A CLINICAL TRIAL APPLICATION IN THE KINGDOM OF BAHRAIN A SHORT GUIDE TO THE PROCEDURE FOR A CLINICAL TRIAL APPLICATION IN THE KINGDOM OF BAHRAIN Version 1 - June 2017 A Short Guide For CT Application 1 2 A Short Guide For CT Application DEFINITIONS Clinical

More information

OFFICE FOR RESEARCH PROCEDURE PROTOCOL & INVESTIGATIONAL BROCHURE, CONTENT, DESIGN, AMENDMENTS & COMPLIANCE

OFFICE FOR RESEARCH PROCEDURE PROTOCOL & INVESTIGATIONAL BROCHURE, CONTENT, DESIGN, AMENDMENTS & COMPLIANCE OFFICE FOR RESEARCH PROCEDURE PROTOCOL & INVESTIGATIONAL BROCHURE, CONTENT, DESIGN, AMENDMENTS & COMPLIANCE 1. Purpose: To describe the procedures related to the development of protocol and investigational

More information

GUIDELINES FOR CONDUCTING CLINICAL TRIALS.

GUIDELINES FOR CONDUCTING CLINICAL TRIALS. GUIDELINES FOR CONDUCTING CLINICAL TRIALS. FOREWORD The purpose of Drug Registration is to ensure that a pharmaceutical product has been adequately tested and evaluated for safety, efficacy and quality,

More information

WHO PQ dossier Module I. DCVMN Common Technical Document (CTD) Workshop Brazil, 18 to 20 June 2018 Dr. Nora Dellepiane

WHO PQ dossier Module I. DCVMN Common Technical Document (CTD) Workshop Brazil, 18 to 20 June 2018 Dr. Nora Dellepiane WHO PQ dossier Module I DCVMN Common Technical Document (CTD) Workshop Brazil, 18 to 20 June 2018 Dr. Nora Dellepiane Introduction The WHO Vaccines prequalification programme has made the decision to use

More information

The new EU clinical trial regulation 536/2014 : Low interventional trials

The new EU clinical trial regulation 536/2014 : Low interventional trials The new EU clinical trial regulation 536/2014 : Low interventional trials KCE Greet Musch Brussels, 28 th November 2017 Agenda: 1: Legal framework EU regulation 536/2014 Q&A document : algorithm 2: Risk

More information

COMMENTS FROM EUROPABIO GENERAL COMMENTS

COMMENTS FROM EUROPABIO GENERAL COMMENTS SUBMISSION OF COMMENTS ON DETAILED GUIDANCE FOR THE REQUEST FOR AUTHORISATION OF A CLINICAL TRIAL ON A MEDICINAL PRODUCT FOR HUMAN USE TO THE COMPETENT AUTHORITIES, NOTIFICATION OF SUBSTANTIAL AMENDMENTS

More information

Vaccine Prequalification Dossier

Vaccine Prequalification Dossier Vaccine Prequalification Dossier Introduction The current process for prequalification of vaccines states that once a product is eligible for prequalification evaluation the manufacturer must submit a

More information

MEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155

MEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155 MEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155 EXECUTIVE SUMMARY Medical device regulations around the world generally require manufacturers of most types of medical devices to supply data as part

More information

ANNEX. CHAPTER I General principles

ANNEX. CHAPTER I General principles ANNEX REGULATIONS on the authorisation by the NMA of clinical trials/notification to the National Medicines Agency of non-interventional studies on medicinal products for human use in Romania CHAPTER I

More information

Investigational New Drug Application

Investigational New Drug Application Investigational New Drug Application Regulatory Sponsor: Funding Sponsor: Study Product: Protocol Number: Name of the Sponsor-Investigator Department Name Address Phone Number Name of Primary Funding Institution

More information

Technical Guidance on Clinical Evaluation of Medical Devices

Technical Guidance on Clinical Evaluation of Medical Devices Annex Technical Guidance on Clinical Evaluation of Medical Devices I. Purpose The clinical evaluation of medical devices is the assessment procedure conducted by registration applicants to validate whether

More information

Sec Short title; finding. Sec Authority to assess and use drug fees. Sec Reauthorization; reporting requirements.

Sec Short title; finding. Sec Authority to assess and use drug fees. Sec Reauthorization; reporting requirements. H.R. 2430, FDA Reauthorization Act of 2017 Section 1. Short Title. This Act may be cited as the FDA Reauthorization Act of 2017. Section 2. Table of Contents Table of Contents TITLE I: FEES RELATING TO

More information

Folder Name Documents included Explanation

Folder Name Documents included Explanation Structure for the documents to be submitted in the case of electronic submission of applications for clinical trials at the BfArM (Federal Institute for Drugs and Medical Devices) / Paul-Ehrlich Institut

More information

Document Reuse: Theory and Practice

Document Reuse: Theory and Practice Document Reuse: Theory and Practice Peggy Boe, RN Sr. Director, Medical Writing Image Solutions, Inc (ISI) Company logo here Best Practice: Single Sourcing Creating reusable text and information Requires

More information

Appendix 3: Another look at the US IND annual report

Appendix 3: Another look at the US IND annual report Appendix 3: Another look at the US IND annual report As the Development Safety Update Report (DSUR) came into effect in late 2011, Chapter 2 (Pharmacovigilance Medical Writing for Clinical Trials) of the

More information

Compassionate Use Navigator Information for Physicians

Compassionate Use Navigator Information for Physicians Compassionate Use Navigator Information for Physicians Contact: Elena Gerasimov, Program Director, Elena@kidsvcancer.org. As a physician, you must have wished there would be more treatment options for

More information

Attachment B: A Guideline for Writing a Clinical Protocol for CPRN

Attachment B: A Guideline for Writing a Clinical Protocol for CPRN Attachment B: A Guideline for Writing a Clinical Protocol for CPRN This document provides guidelines for protocol submission. It is only guidance, and the format in which you choose to present the information

More information

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Ref. Ares(2013)2581479-05/07/2013 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products authorisations, EMA Brussels, date ENTR/6283/00 Rev 4 orphan\guidelines\format

More information

1. Checklist for Grant of permission to manufacture/import of Bulk Drug already approved in the country

1. Checklist for Grant of permission to manufacture/import of Bulk Drug already approved in the country 1. Checklist for Grant of permission to manufacture/import of Bulk Drug already approved in the country S no 1. Name of Applicant with address 2. Name of Drug 3. Therapeutic Class 4. Date of Approval Documents

More information

RSC/CT Det. no. 1/2013

RSC/CT Det. no. 1/2013 RSC/CT Det. no. 1/2013 Protocol 1631-P The English version of this Determination was prepared in order to help comprehension by non-italian mother tongue users, but is NOT an official document. Please

More information

Standard Operating Procedure (SOP) Research and Development Office

Standard Operating Procedure (SOP) Research and Development Office Standard Operating Procedure (SOP) Research and Development Office Title of SOP: Creation & Maintenance of an Investigator Brochure SOP Number: 34 Version Number: 1.0 Supercedes: N/A Effective date: August

More information

Technical Guidance on Clinical Evaluation of Medical Devices 1

Technical Guidance on Clinical Evaluation of Medical Devices 1 Technical Guidance on Clinical Evaluation of Medical Devices 1 I. Purpose The clinical evaluation of medical devices is the assessment procedure conducted by registration applicants to validate whether

More information

EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL QUESTIONS. and ANSWERS

EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL QUESTIONS. and ANSWERS EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, F2/SM D (2008) QUESTIONS and ANSWERS The rules governing medicinal products in the European Union VOLUME 2 NOTICE

More information

Author Signature: Date: 10 October 2017 The author is signing to confirm the technical content of this document

Author Signature: Date: 10 October 2017 The author is signing to confirm the technical content of this document SOP Title: Investigator s Brochure Content, Design, Amendments, Filing & Distribution Author: Clinical Research and Development Office (CRDO) Author Signature: Date: 10 October 2017 The author is signing

More information

Office for Human Subject Protection. University of Rochester

Office for Human Subject Protection. University of Rochester POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,

More information

Inspection of the conduct of clinical evaluations on medical devices in the premises of healthcare providers

Inspection of the conduct of clinical evaluations on medical devices in the premises of healthcare providers ZP-21 Inspection of the conduct of clinical evaluations on medical devices in the premises of healthcare providers This guideline supersedes guideline SÚKL PZT-16 as of November 1, 2004. The purpose of

More information

Subpart H [Reserved] Subpart I Expanded Access to Investigational Drugs for Treatment. 21 CFR Ch. I ( Edition)

Subpart H [Reserved] Subpart I Expanded Access to Investigational Drugs for Treatment. 21 CFR Ch. I ( Edition) 312.300 (c) Disposition of unused drug. The person who ships the drug under paragraph (a) of this section shall assure the return of all unused supplies of the drug from individual investigators whenever

More information

Global Clinical Trial

Global Clinical Trial 1. Application For Global Clinical trial Sr. Contents 1. Name & Address of the Applicant:- 2. Name & Address of the Sponsor:- 3. Authorization Letter from Sponsor in favour of Applicant:- 4. Treasury Challan

More information

This is a controlled document. The master document is posted on the JREO website and any print-off will be classed as uncontrolled.

This is a controlled document. The master document is posted on the JREO website and any print-off will be classed as uncontrolled. Standard Operating Procedure (SOP) Investigator Preparation of Annual Developmental Safety and Update Report (DSUR) and its review and submission by the Sponsor SOP ID number: JREOSOP0008 Effective Date:

More information

How to put together an IND application

How to put together an IND application How to put together an IND application Judit Milstein, Chief, Project Management Staff Judit.milstein@fda.hhs.gov Eithu Lwin, Regulatory Health Project Manager Eithu.Lwin@fda.hhs.gov Division of Transplant

More information

Guide for National Scientific and Regulatory Advice

Guide for National Scientific and Regulatory Advice Guide for National Scientific and Regulatory Advice ADV-G0017-3 DATE 18 JULY 2017 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS

More information

Guidelines: c. Providing the investigational drug for the requested use will not interfere with the initiation, conduct, or completion of clinical

Guidelines: c. Providing the investigational drug for the requested use will not interfere with the initiation, conduct, or completion of clinical Guidelines for the Submission of an Expanded Access IND to Permit Diagnosis, Monitoring or Treatment of Intermediate-size Patient Populations with an Investigational Drug or a REMS-restricted, Approved

More information

VERSION: 21 st June Date of Publication: 15 th March C/ CAMPEZO, 1 EDIFICIO MADRID Tel.: Fax:

VERSION: 21 st June Date of Publication: 15 th March C/ CAMPEZO, 1 EDIFICIO MADRID Tel.: Fax: Memorandum on Collaboration and Exchange of Information between the Spanish Agency of Medicinal Products and Medical Devices and Ethics Committees for investigation with medicinal products VERSION: 21

More information

MEDICAL DEVICE. Technical file.

MEDICAL DEVICE. Technical file. MEDICAL DEVICE Technical file www.icaro-research.eu ICARO MDTF v1.0 1 Mar 2016 1. Do you plan to launch your medical device in Europe? If you re reading this, chances are good that you re considering introducing

More information

1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.

1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products. 1.1 Adverse Drug Reaction (ADR) In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established: all noxious and unintended

More information

Documentation requirements for an initial consultation

Documentation requirements for an initial consultation Language : French or English Documentation requirements for an initial consultation Because of the wide range of medical devices which incorporate, as an integral part, an ancillary medicinal substance,

More information

Clinical Trial Basics:

Clinical Trial Basics: Clinical Trial Basics: Components and Responsibilities Pre-Award Aida Nana Ama Manu, Project Coordinator Four Main Components Non-Disclosure Agreements Institutional Review Board Application Clinical Trial

More information

GUIDANCE FOR CLINICAL TRIAL SPONSORS Clinical Trial Applications

GUIDANCE FOR CLINICAL TRIAL SPONSORS Clinical Trial Applications GUIDANCE FOR CLINICAL TRIAL SPONSORS Published by authority of the Minister of Health Date Adopted 2003/06/11 Effective Date 2003/06/25 Administrative Changes Date 2008/02/27 Health Products and Food Branch

More information

Regulation issued by the Federal Office for Safety in Health Care regarding the Schedule of Fees pursuant to the GESG Act

Regulation issued by the Federal Office for Safety in Health Care regarding the Schedule of Fees pursuant to the GESG Act Please be aware that we can not guarantee the correctness of the translation nor that the content of the fee regulation is complete or accurate. To make sure you have the correct and complete version you

More information

QUESTIONS AND ANSWERS ON THE PAEDIATRIC REGULATION (REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL (EC) No 1901/2006, AS AMENDED)

QUESTIONS AND ANSWERS ON THE PAEDIATRIC REGULATION (REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL (EC) No 1901/2006, AS AMENDED) QUESTIONS AND ANSWERS ON THE PAEDIATRIC REGULATION (REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL (EC) No 1901/2006, AS AMENDED) ARTICLE 45 & 46 October 2007 Revision 4, November 2008 Question

More information

KLH-21 version 7 With effect from the date of issue (effective date 20th July 2018), this guideline supersedes guideline KLH-21, version 6.

KLH-21 version 7 With effect from the date of issue (effective date 20th July 2018), this guideline supersedes guideline KLH-21, version 6. KLH-21 version 7 Reporting Adverse Reactions to Medicinal Products for Human Use in a Clinical Trial and to Medicinal Products without Marketing Authorisation The guideline is being issued on the basis

More information

Clinical aspects during Prequalification of vaccines. Olivier Lapujade World Health Organization, EMP/RHT/PQT

Clinical aspects during Prequalification of vaccines. Olivier Lapujade World Health Organization, EMP/RHT/PQT Clinical aspects during Prequalification of vaccines Olivier Lapujade World Health Organization, EMP/RHT/PQT lapujadeo@who.int 1 Chapter 8: Clinical experience Note 1 : Reference documents TRS 978, Annex

More information

Investigator-Initiated INDs

Investigator-Initiated INDs Investigator-Initiated INDs Marjorie Small, RN, CCRC Office of Clinical Research 23 May 2011 PPHS/IRB Research Grand Rounds Outline of Presentation I. What is an IND? II. Code of Federal Regulations III.

More information

Research & Development. J Illingworth and S Moffat. Research, pharmacy and R&D staff

Research & Development. J Illingworth and S Moffat. Research, pharmacy and R&D staff Department Title of SOP Research & Development SOP reference no: R&D GCP SOP 08 Authors: Reviewed by Current version number and date: J H Pacynko J Illingworth and S Moffat Version 4, 04.02.19 Next review

More information

MANUAL: Administrative Policy & Procedure Manual POLICY:

MANUAL: Administrative Policy & Procedure Manual POLICY: SJMHS Locations: St. Joseph Mercy Ann Arbor, St. Joseph Mercy Chelsea, St. Joseph Mercy Livingston, St. Mary Mercy Livonia MANUAL: Administrative Policy & Procedure Manual POLICY: Expanded access is the

More information

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Public health and Risk assessment Pharmaceuticals Brussels, 01 June 2010 SANCO/C/8/SF/dn D(2010) 326199 THE RULES GOVERNING MEDICINAL PRODUCTS

More information

Tanzania Food, Drugs And Cosmetics (Clinical Trials Control) THE TANZANIA FOOD, DRUGS AND COSMETICS ACT ARRANGEMENT OF REGULATIONS

Tanzania Food, Drugs And Cosmetics (Clinical Trials Control) THE TANZANIA FOOD, DRUGS AND COSMETICS ACT ARRANGEMENT OF REGULATIONS GOVERNMENT NOTICE NO. 53.published on 15/03/2013 THE TANZANIA FOOD, DRUGS AND COSMETICS ACT ARRANGEMENT OF REGULATIONS Regulation Title PART I PRELIMINARY PROVISIONS 1. Short title and commencement. 2.

More information

MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION (Minzdrav of Russia) Moscow

MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION (Minzdrav of Russia) Moscow 1 MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION (Minzdrav of Russia) ORDER 9 January 2014 No. 2n Moscow On Approval of the Procedure for Medical Device Conformity Assessment in the Form of Technical Trials,

More information

Regulatory requirements and registration process of Generic Drugs in China

Regulatory requirements and registration process of Generic Drugs in China 13 Regulatory requirements and registration process of Generic Drugs in China Jitendra Kumar Badjatya Deputy Manager-DRA, Montajat Pharmaceutical Company Limited, Dammam, KSA jeetbadjatya@gmail.com ABSTRACT

More information

DECREE - 8,077, OF AUGUST 14TH, 2013

DECREE - 8,077, OF AUGUST 14TH, 2013 DECREE - 8,077, OF AUGUST 14TH, 2013 Regulates the registro, control, and monitoring of the products addressed by Law 6,360, of September 23rd, 1976, and the conditions for the operation of companies subject

More information

GUIDELINES ON MEDICAL DEVICES GUIDE FOR COMPETENT AUTHORITIES IN MAKING AN ASSESSMENT OF CLINICAL INVESTIGATION NOTIFICATION

GUIDELINES ON MEDICAL DEVICES GUIDE FOR COMPETENT AUTHORITIES IN MAKING AN ASSESSMENT OF CLINICAL INVESTIGATION NOTIFICATION EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Cosmetics and Medical Devices MEDDEV 2.7.2 December 2008 GUIDELINES ON MEDICAL DEVICES GUIDE FOR COMPETENT AUTHORITIES IN

More information

F.No /13-DC (Pt-13A ) Office of Drugs Controller General (India) New Drugs Division

F.No /13-DC (Pt-13A ) Office of Drugs Controller General (India) New Drugs Division F.No. 12-01/13-DC (Pt-13A ) Office of Drugs Controller General (India) New Drugs Division Subject: System of Pre-screening for submission of reports of SAEs to CDSCO The Drugs & Cosmetics Rules have been

More information

Consultation by a notified body on an ancillary medicinal substance integrated in a medical device

Consultation by a notified body on an ancillary medicinal substance integrated in a medical device Consultation by a notified body on an ancillary medicinal substance integrated in a medical device Documentation requirements for an initial consultation Language : French or English Because of the wide

More information

GCP/Clinical Investigation in Japan

GCP/Clinical Investigation in Japan GCP/Clinical Investigation in Japan 27-28 August, 2018 Shinwa Shibata Office of Non-clinical and Clinical Compliance Pharmaceuticals and Medical Devices Agency 1 Today s Agenda 1. Japanese-GCP (J-GCP)

More information

Clinical Development and enabling Regulatory Steps: How to obtain ODD and Scientific Advice at EMA

Clinical Development and enabling Regulatory Steps: How to obtain ODD and Scientific Advice at EMA Clinical Development and enabling Regulatory Steps: How to obtain ODD and Scientific Advice at EMA TELETHON Convention, Riva del Garda (TN) 15 March 2017 Michela Gabaldo Head Alliance Management & Regulatory

More information

Risk-Based Monitoring: How Can It Be Implemented For More Effective Study Oversight

Risk-Based Monitoring: How Can It Be Implemented For More Effective Study Oversight Risk-Based Monitoring: How Can It Be Implemented For More Effective Study Oversight Lisa Marie Saldanha Senior Director & Head of Operations Real World Insights Asia Singapore Research & Ethics Conference

More information

ARQUIVOS BRASILEIROS DE CARDIOLOGIA (BRAZILIAN ARCHIVES OF CARDIOLOGY) GUIDELINES FOR PUBLICATION

ARQUIVOS BRASILEIROS DE CARDIOLOGIA (BRAZILIAN ARCHIVES OF CARDIOLOGY) GUIDELINES FOR PUBLICATION 1 ARQUIVOS BRASILEIROS DE CARDIOLOGIA (BRAZILIAN ARCHIVES OF CARDIOLOGY) GUIDELINES FOR PUBLICATION 1. The Brazilian Archives of Cardiology (Arq Bras Cardiol) is a monthly publication of the Brazilian

More information

Regulatory Affairs: Study Report of New Drug Registration Process in European Union

Regulatory Affairs: Study Report of New Drug Registration Process in European Union 95 Review Article Regulatory Affairs: Study Report of New Drug Registration Process in European Union Yogeshkumar B. Viradiya*, Manoj B. Dagwar, Swapnil T. Lanjewar Department of Regulatory Affairs, Institute

More information

Explanatory note on fees payable to the European Medicines Agency

Explanatory note on fees payable to the European Medicines Agency 30 March 2015 EMA/167155/2014 Executive Director Explanatory note on s payable to the European Medicines Agency The s, exemptions and definitions described in this Explanatory Note apply as of 1 April

More information

Current Biologics Regulatory Scenario in Brazil

Current Biologics Regulatory Scenario in Brazil LATAM CMC Strategy Forum 2019 Current Biologics Regulatory Scenario in Brazil Carolina Damas Rocha Zarate Blades, PhD Office of Biological Products Brazilian Health Regulatory Agency ANVISA Brazil, March/2019

More information

Re: Docket No. FDA-2015-D-4562: Draft Guidance Safety Assessment for IND Safety Reporting

Re: Docket No. FDA-2015-D-4562: Draft Guidance Safety Assessment for IND Safety Reporting February 16, 2016 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA-2015-D-4562: Draft Guidance Safety Assessment for IND

More information

REGULATION (EC) No 542/95

REGULATION (EC) No 542/95 REGULATION (EC) No 542/95 Commission Regulation (EC) No 542/95 of 10 March 1995 concerning the examination of variations to the terms of a marketing authorization falling within the scope of Council Regulation

More information

The rules governing medicinal products in the European Union. Presentation and content of the dossier Edition

The rules governing medicinal products in the European Union. Presentation and content of the dossier Edition The rules governing medicinal products in the European Union Volume 2B Notice to Applicants Medicinal products for human use Presentation and content of the dossier 1998 Edition EUROPEAN COMMISSION Directorate

More information

Structure and content of an IMPD. What is required for first into man trial?

Structure and content of an IMPD. What is required for first into man trial? What is required for first into man? The EU IMPD Thomas Sudhop, MD Scope Structure and content of an IMPD What is required for first into man trial? Only for IMPs that do not have a marketing authorisation

More information

September 12, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852

September 12, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 September 12, 2013 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Re: : Draft Guidance for Industry on Pediatric Study Plans: Content

More information

Initial Draft Discussion Document for A Canadian Orphan Drug Regulatory Framework

Initial Draft Discussion Document for A Canadian Orphan Drug Regulatory Framework Initial Draft Discussion Document for A Canadian Orphan Drug Regulatory Framework Table of Contents Preamble... 3 Background... 3 What is a rare disease?... 3 What is an orphan drug?... 3 Unique Challenges

More information

Russian Federation. Chapter 12. By Julianna Tabastajewa and Svetlana Rudevich

Russian Federation. Chapter 12. By Julianna Tabastajewa and Svetlana Rudevich Chapter 12 Russian Federation By Julianna Tabastajewa and Svetlana Rudevich Legal System The Russian Federation is a federal state consisting of a total of 83 republics, regions, federal cities, autonomous

More information

MANUFACTURE OF INVESTIGATIONAL MEDICINAL PRODUCTS

MANUFACTURE OF INVESTIGATIONAL MEDICINAL PRODUCTS ANNEX 13 MANUFACTURE OF INVESTIGATIONAL MEDICINAL PRODUCTS Introduction Medicinal products intended for research and development trials are not at present subject either to marketing or manufacturing Community

More information

REGISTRATION OF MEDICAL DEVICE. SUBMISSION & APPLICATION By IDAMAZURA IDRIS MEDICAL DEVICE AUTHORITY

REGISTRATION OF MEDICAL DEVICE. SUBMISSION & APPLICATION By IDAMAZURA IDRIS MEDICAL DEVICE AUTHORITY REGISTRATION OF MEDICAL DEVICE SUBMISSION & APPLICATION By IDAMAZURA IDRIS MEDICAL DEVICE AUTHORITY Medical device: regulated item under the Medical Device Act 2012 (Act 737) and its regulation The objective:

More information

Technical Guidelines for Clinical Evaluation on Medical Devices

Technical Guidelines for Clinical Evaluation on Medical Devices Appendix Technical Guidelines for Clinical Evaluation on Medical Devices I. Preparation Objective The clinical evaluation of medical devices refers to the process for conforming whether the products meet

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/42832/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR

More information

Structure and Mandate of FDA

Structure and Mandate of FDA Structure and Mandate of FDA Leonard Sacks, M.D. Office of Medical Policy Center for Drug Evaluation and Research FDA FDA Clinical Investigator Training Course November 13, 2018 Mission of regulatory agencies

More information

Orphan Designation System in Japan. 10, March 2014 Ministry of Health, Labour and Welfare

Orphan Designation System in Japan. 10, March 2014 Ministry of Health, Labour and Welfare Orphan Designation System in Japan 10, March 2014 Ministry of Health, Labour and Welfare Background of the Orphan Designation System Before the system had been implemented, the R&D on medicines for rare

More information

NOTICE. Subject: Stakeholders suggestions/comments on Clinical Trials conductance in India

NOTICE. Subject: Stakeholders suggestions/comments on Clinical Trials conductance in India NOTICE Dated: 28.07.2014 Subject: Stakeholders suggestions/comments on Clinical Trials conductance in India During the briefing on CDSCO, Hon ble Minister of Health & Family Welfare desired that there

More information

I. Purpose. II. Definitions. Last Approval Date

I. Purpose. II. Definitions. Last Approval Date Investigational Drugs and Biologics Page 1 of 13 I. Purpose The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics

More information

The final recommendations of the workgroups were that the CPT process should:

The final recommendations of the workgroups were that the CPT process should: CPT Category III Codes: The First Ten Years (An excerpt from the May 2009 CPT Assistant) The addition of the new Category III section was announced in the February 2001 issue of the CPT Assistant. Guidelines

More information

DFG. Proposal Preparation Instructions. Clinical Trials Draft Proposals. DFG form /14 page 1 of 8

DFG. Proposal Preparation Instructions. Clinical Trials Draft Proposals. DFG form /14 page 1 of 8 form 17.03 10/14 page 1 of 8 Proposal Preparation Instructions Clinical Trials Draft Proposals form 17.03 10/14 page 2 of 8 Please write your proposal in English and use the Draft Proposal Template ( form

More information

Comments and suggestions from reviewer

Comments and suggestions from reviewer Comments and suggestions from reviewer Page 1 of 13 Title: WHO Guidelines on the Quality, Safety, and Efficacy of Biological Medicinal Products Prepared by Recombinant DNA Technology: WHO/rDNA_DRAFT/12

More information

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL STUDY PROTOCOL CHAPTER 14 REVISED: OCTOBER 2015

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL STUDY PROTOCOL CHAPTER 14 REVISED: OCTOBER 2015 THE STUDY PROTOCOL The study protocol is a written document detailing how a clinical trial is conducted. The elements of a protocol include: 1. Trial design and organization; 2. Study objectives; 3. Background

More information

Global Clinical Trial

Global Clinical Trial 1. Application For Global Clinical trial Sr. Contents 1. Name & Address of the Applicant:- 2. Name & Address of the Sponsor:- 3. Authorization Letter from Sponsor in favour of Applicant:- 4. Treasury Challan

More information

Chin Koerner Executive Director US Regulatory and Development Policy

Chin Koerner Executive Director US Regulatory and Development Policy Chin Koerner Executive Director US Regulatory and Development Policy Novartis Pharmaceuticals Corporation 1700 Rockville Pike Suite 510 Rockville, MD 20852 Tel 301.468.5607 Fax 301.468.5614 Email: Chin.Koerner@novartis.com

More information

GUIDELINE REGARDING COLLECTION, VERIFICATION, AND SUBMISSION OF THE REPORTS OF ADVERSE EVENTS / REACTIONS OCCURRING IN CLINICAL DRUG TRIALS

GUIDELINE REGARDING COLLECTION, VERIFICATION, AND SUBMISSION OF THE REPORTS OF ADVERSE EVENTS / REACTIONS OCCURRING IN CLINICAL DRUG TRIALS 1. PURPOSE This guideline is about the collection, verification, and submission of the reports of adverse events / reactions occurring in clinical drug trials, and code breaking methods. 2. DEFINITIONS

More information

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor. POLICY #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional

More information

Draft proposal for an addendum, on transparency, to the Functional specifications for the EU portal and EU database to be audited - EMA/42176/2014

Draft proposal for an addendum, on transparency, to the Functional specifications for the EU portal and EU database to be audited - EMA/42176/2014 20 January 2015 EMA/641479/2014 Compliance and Inspections Draft proposal for an addendum, on transparency, to the Functional specifications for the EU portal and EU database to be audited - EMA/42176/2014

More information

DRUG REGISTRATION REGULATION

DRUG REGISTRATION REGULATION DRUG REGISTRATION REGULATION Registration Categories and Application Information Requirements of Chemical Drugs I Registration Categories 1) New chemical entity never marketed in any country. i. Drug substance

More information

MAINTENANCE OF THE ICH GUIDELINE ON NON-CLINICAL SAFETY STUDIES FOR THE CONDUCT OF HUMAN CLINICAL TRIALS FOR PHARMACEUTICALS M3(R1)

MAINTENANCE OF THE ICH GUIDELINE ON NON-CLINICAL SAFETY STUDIES FOR THE CONDUCT OF HUMAN CLINICAL TRIALS FOR PHARMACEUTICALS M3(R1) INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE MAINTENANCE OF THE ICH GUIDELINE ON NON-CLINICAL

More information

Pharmaceutical traceability in Brazil

Pharmaceutical traceability in Brazil Pharmaceutical traceability in Brazil Ms. Bianca Zimon Giacomini Ribeiro, Deputy Chief Adviser for International Affairs, National Agency of Sanitary Surveillance (Anvisa), Brazil 18 October 2017 GS1 2017

More information

Guidelines for application for Registration of Medicinal Products 2006(DRA)

Guidelines for application for Registration of Medicinal Products 2006(DRA) Contact details: Drug Regulatory Authority, Thimphu Bhutan Telephone # 00975-2-334271, Fax: 00975-2-335803 Email : dra@health.gov.bt URL : www.health.gov.bt/dra.php Page 1 of 10 The guidelines outlined

More information

CLINICAL TRIAL AUTHORIZATION APPLICATION FORM

CLINICAL TRIAL AUTHORIZATION APPLICATION FORM CLINICAL TRIAL AUTHORIZATION APPLICATION FORM Date of Receipt: Date of Triage : Date of valid application: Type of CTC review: NHRA CTA Number: ICTR/ITN Number: Date of Verification of ICTR/ITN: THIS SECTION

More information

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor. SOP #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional responsibilities

More information

Explanatory note on general fees payable to the European Medicines Agency

Explanatory note on general fees payable to the European Medicines Agency Explanatory note on general fees payable to the European Medicines Agency The fees, fee exemptions and definitions described in this explanatory note apply as of 1 June 2017 and are based on Council Regulation

More information

Expanded Access and the Individual Patient IND

Expanded Access and the Individual Patient IND Expanded Access and the Individual Patient IND Research Wednesdays April 26, 2017 Erika Segear Johnson, PhD, RAC Associate Director of Regulatory Affairs Office of Regulatory Affairs and Quality Office

More information

FDA Audit Preparation

FDA Audit Preparation Duke University Office of Audit, Risk and Compliance (OARC) FDA Audit Preparation Margaret M. Groves, JD, CRA, CCRP, CHRC Associate Compliance Officer, Research Compliance Assurance (RCA) External audits

More information

S9 Nonclinical Evaluation for Anticancer Pharmaceuticals

S9 Nonclinical Evaluation for Anticancer Pharmaceuticals S9 Nonclinical Evaluation for Anticancer Pharmaceuticals This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create

More information

Approved by Resolution of the Ministry of Health of the Republic of Belarus No. 55 dated April 23, 2015

Approved by Resolution of the Ministry of Health of the Republic of Belarus No. 55 dated April 23, 2015 RESOLUTION of the Ministry of Health of the Republic of Belarus No. 55 dated April 23, 2015 On certain measures on realization of the Resolution of the Council of Ministers of the Republic of Belarus No.

More information

Panama City, Panama April, 12-15, Marcelo Mario Matos Moreira. The Brazilian Health Surveillance Agency (ANVISA)

Panama City, Panama April, 12-15, Marcelo Mario Matos Moreira. The Brazilian Health Surveillance Agency (ANVISA) DIA Latin American Regulatory Conference Panama City, Panama April, 12-15, 2011 Biosimilars/Biotechnology Marcelo Mario Matos Moreira Coordinator Office of Biological Products The Brazilian Health Surveillance

More information